$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040986 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$2.213M	$300.2K	$2.350K
YoY Change	94085.53%	26007.48%
Cost Of Revenue	$1.665M	$74.70K	$180.00
YoY Change	924822.22%	51067.12%
Gross Profit	$548.5K	$223.8K	$2.170K
YoY Change	25176.5%	22166.67%
Gross Profit Margin	24.78%	74.53%	92.34%
Selling, General & Admin	$2.214M	$2.024M	$1.429M
YoY Change	54.97%	239.31%	62.21%
% of Gross Profit	403.64%	904.42%	65836.87%
Research & Development	$528.2K	$330.4K	$197.3K
YoY Change	167.77%	3.33%	-85.12%
% of Gross Profit	96.29%	147.63%	9089.86%
Depreciation & Amortization	$149.6K	$23.50K	$7.330K
YoY Change	1940.79%	2951.95%	130.5%
% of Gross Profit	27.27%	10.5%	337.79%
Operating Expenses	$2.891M	$2.518M	$1.626M
YoY Change	77.8%	157.71%	-26.32%
Operating Profit	-$2.342M	-$2.295M	-$1.624M
YoY Change	44.26%	135.06%
Interest Expense	-$13.16K	$8.785K	-$50.84K
YoY Change	-74.11%	-99.01%	-98.83%
% of Operating Profit
Other Income/Expense, Net	-$15.30K	-$10.00K
YoY Change
Pretax Income	-$2.371M	-$2.289M	-$1.675M
YoY Change	41.58%	-53.48%	-73.52%
Income Tax	$2.290K	$2.294K	$0.00
% Of Pretax Income
Net Earnings	-$2.373M	-$2.291M	-$1.675M
YoY Change	41.72%	-53.43%	-73.53%
Net Earnings / Revenue	-107.22%	-763.03%	-71258.72%
Basic Earnings Per Share		-$0.26
Diluted Earnings Per Share	-$0.25	-$0.26	-$0.37
COMMON SHARES
Basic Shares Outstanding	9.502M shares	8.783M shares	8.370M shares
Diluted Shares Outstanding		8.697M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.822M	$4.510M	$11.41M
YoY Change	-75.28%	-66.59%
Cash & Equivalents	$2.800M	$4.500M	$11.40M
Short-Term Investments
Other Short-Term Assets	$321.0K	$380.0K	$531.9K
YoY Change	-39.65%	-29.8%
Inventory	$18.48K	$9.908K	$5.540K
Prepaid Expenses
Receivables	$811.7K	$1.110M	$10.49K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.973M	$6.010M	$11.96M
YoY Change	-66.79%	-57.24%	731.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$458.6K	$512.2K	$214.4K
YoY Change	113.88%	28656.43%	4528.49%
Goodwill	$1.404M	$1.149M
YoY Change
Intangibles	$833.5K	$848.1K	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.06K	$16.06K	$6.000K
YoY Change	167.67%	167.67%	140.0%
Total Long-Term Assets	$4.249M	$4.179M	$220.4K
YoY Change	1827.44%	53611.03%	1362.28%
TOTAL ASSETS
Total Short-Term Assets	$3.973M	$6.010M	$11.96M
Total Long-Term Assets	$4.249M	$4.179M	$220.4K
Total Assets	$8.222M	$10.19M	$12.18M
YoY Change	-32.51%	-27.54%	738.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$604.8K	$827.4K	$345.0K
YoY Change	75.28%	452.09%	49.75%
Accrued Expenses	$1.150M	$643.8K	$541.9K
YoY Change	112.18%	35.81%	12.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$251.7K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$365.5K	$360.0K
YoY Change
Total Short-Term Liabilities	$2.248M	$1.959M	$1.139M
YoY Change	97.41%	33.77%	-91.27%
LONG-TERM LIABILITIES
Long-Term Debt	$835.5K	$930.0K	$0.00
YoY Change
Other Long-Term Liabilities	$283.0K	$310.0K
YoY Change
Total Long-Term Liabilities	$1.118M	$1.240M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.248M	$1.959M	$1.139M
Total Long-Term Liabilities	$1.118M	$1.240M	$0.00
Total Liabilities	$3.366M	$3.196M	$1.139M
YoY Change	195.63%	118.25%	-91.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.60M	-$42.20M	-$36.70M
YoY Change	21.53%	20.57%	28.71%
Common Stock	$65.76K	$64.54K	$58.67K
YoY Change	12.09%	10.15%	213.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.855M	$6.994M	$11.04M
YoY Change
Total Liabilities & Shareholders Equity	$8.222M	$10.19M	$12.18M
YoY Change	-32.51%	-27.54%	738.23%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$2.373M	-$2.291M	-$1.675M
YoY Change	41.72%	-53.43%	-73.53%
Depreciation, Depletion And Amortization	$149.6K	$23.50K	$7.330K
YoY Change	1940.79%	2951.95%	130.5%
Cash From Operating Activities	-$1.618M	-$1.530M	-$1.301M
YoY Change	24.39%	-13.07%	-21.48%
INVESTING ACTIVITIES
Capital Expenditures	-$17.10K	$0.00	$220.0K
YoY Change	-107.77%
Acquisitions
YoY Change
Other Investing Activities	$3.500K	-$2.190M
YoY Change
Cash From Investing Activities	$10.60K	-$2.180M	-$220.0K
YoY Change	-104.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-84.98K	-50.00K	-563.6K
YoY Change	-84.92%	-100.33%	-120.2%
NET CHANGE
Cash From Operating Activities	-1.618M	-1.530M	-1.301M
Cash From Investing Activities	10.60K	-2.180M	-220.0K
Cash From Financing Activities	-84.98K	-50.00K	-563.6K
Net Change In Cash	-1.692M	-3.760M	-2.084M
YoY Change	-18.81%	-128.31%	-283.98%
FREE CASH FLOW
Cash From Operating Activities	-$1.618M	-$1.530M	-$1.301M
Capital Expenditures	-$17.10K	$0.00	$220.0K
Free Cash Flow	-$1.601M	-$1.530M	-$1.521M
YoY Change	5.27%		-8.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001712762
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	BIAF	Finance Lease Right To Use Net FinanceLeaseRightToUseNet		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
	us-gaap	Accretion Expense AccretionExpense		usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	BIAF	Common Stock Issuance For Acquisition Of Subsidiary CommonStockIssuanceForAcquisitionOfSubsidiary		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
	BIAF	Fair Value Of Warrants Issued To Placement Agents FairValueOfWarrantsIssuedToPlacementAgents		usd
	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes		usd
CY2022Q4	BIAF	Laboratory Services LaboratoryServices		usd
CY2022Q4	BIAF	Purchased Receivables From Acquisition Net Of Collections PurchasedReceivablesFromAcquisitionNetOfCollections		usd
CY2022Q4	BIAF	Net Patient Fees Receivable NetPatientFeesReceivable		usd
CY2022Q4	BIAF	Histology Fees HistologyFees		usd
CY2022Q4	BIAF	Medical Director Fees MedicalDirectorFees		usd
CY2022Q4	BIAF	Billing Fees BillingFees		usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
	us-gaap	Lease Cost LeaseCost		usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization		usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization		usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability		usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent		pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent		pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41463
	dei	Entity Registrant Name EntityRegistrantName	bioAffinity Technologies, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5211056
	dei	Entity Address Address Line1 EntityAddressAddressLine1	22211 W. Interstate 10
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1206
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Antonio
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78257
	dei	City Area Code CityAreaCode	(210)
	dei	Local Phone Number LocalPhoneNumber	698-5334
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9502243	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4509236	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11413759	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1108414	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	10489	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	9908	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5540	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	382651	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	6010209	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11961687	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	512152	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	392347	usd
CY2023Q3	BIAF	Finance Lease Right To Use Net FinanceLeaseRightToUseNet	1262087	usd
CY2023Q3	us-gaap	Goodwill Goodwill	1148553	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	848056	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16060	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	usd
CY2023Q3	us-gaap	Assets Assets	10189464	usd
CY2022Q4	us-gaap	Assets Assets	12182125	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	827407	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	345042	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	643786	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	38250	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	90863	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	358282	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	251746	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1958588	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1138682	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	929570	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	307397	usd
CY2023Q3	us-gaap	Liabilities Liabilities	3195555	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1138682	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9216883	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9216883	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8381324	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	64535	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	58669	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49160689	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47652242	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42231315	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36667468	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6993909	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10189464	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12182125	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298484	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1150	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	319143	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2457	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	74704	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	146	usd
	us-gaap	Cost Of Revenue CostOfRevenue	76025	usd
	us-gaap	Cost Of Revenue CostOfRevenue	292	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	223780	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1004	usd
	us-gaap	Gross Profit GrossProfit	243118	usd
	us-gaap	Gross Profit GrossProfit	2165	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	330376	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	319744	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1035118	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	949388	usd
CY2023Q3	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	106422	usd
CY2022Q3	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	60941	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	161310	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	141684	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2023917	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	595702	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4576708	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1295558	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	57569	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	773	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100805	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2852	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2518284	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	977160	usd
	us-gaap	Operating Expenses OperatingExpenses	5873941	usd
	us-gaap	Operating Expenses OperatingExpenses	2389482	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2294504	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-976156	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5630823	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2387317	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	27193	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7414	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	109971	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8261	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	8785	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	896502	usd
	us-gaap	Interest Expense InterestExpense	11801	usd
	us-gaap	Interest Expense InterestExpense	2443350	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4606	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4606	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	17100	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	17100	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
CY2022Q3	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-3053914	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2288590	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4919158	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5545147	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6477070	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2294	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18700	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2460	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2290884	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4919458	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5563847	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6479530	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.03
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8696554	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8696554	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4203781	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4203781	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8551154	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8551154	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3194765	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3194765	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	514313	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5563847	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6993909	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8098348	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	186445	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2290884	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6993909	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	211745	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	348219	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	-185	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	383696	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6027414	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4044318	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16065332	usd
	BIAF	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	7713310	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74900	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6479530	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12598500	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16786329	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16786329	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	79013	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	134277	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	165723	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6027414	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4044318	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16065332	usd
CY2022Q3	BIAF	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	7713310	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74900	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4919458	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12598500	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12598500	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5563847	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6479530	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100805	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2852	usd
	us-gaap	Accretion Expense AccretionExpense	1972948	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	514313	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	211745	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-71840	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	8400	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4368	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5715	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-152768	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	502177	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	406836	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-80725	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-144013	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1524	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	465653	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	38250	usd
	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	5913	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4421503	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2770209	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36344	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2186497	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2222841	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6027414	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7713310	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74900	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	555148	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	251746	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	31612	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	8433	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	724000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	100000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	55651	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-260179	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14907509	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6904523	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12137300	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1360638	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4509236	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13497938	usd
	us-gaap	Interest Paid Net InterestPaidNet	11801	usd
	us-gaap	Interest Paid Net InterestPaidNet	2459	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	18700	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3945	usd
	BIAF	Common Stock Issuance For Acquisition Of Subsidiary CommonStockIssuanceForAcquisitionOfSubsidiary	1000000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4044318	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	16065332	usd
	BIAF	Fair Value Of Warrants Issued To Placement Agents FairValueOfWarrantsIssuedToPlacementAgents	383696	usd
	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes	348219	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42200000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4500000	usd
CY2023Q3	BIAF	Total Assets Percent TotalAssetsPercent	0.44	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zydnHLuihVa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zPiggF7PAQFh">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation allowance on the Company’s deferred tax assets, stock-based compensation, valuation of goodwill and intangible assets related to the business combination, allowance for contractual adjustments and discounts related to service revenues, and the useful lives of fixed assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	2500000	usd
CY2023Q3	BIAF	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Common Stock BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCommonStock	1000000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	3500000	usd
CY2023Q3	BIAF	Net Working Capital NetWorkingCapital	1167000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	326000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	8000	usd
CY2023Q3	BIAF	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Customer Relationships BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships	700000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	150000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	1149000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	3500000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zInBqkFzrxI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zBW9iBMNgrDi">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zIygYiEvgfd4" title="Federal insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Advertising Expense AdvertisingExpense	43000	usd
	us-gaap	Advertising Expense AdvertisingExpense	13000	usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	10000	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	5000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5333647	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5514717	shares
CY2023Q3	us-gaap	Revenues Revenues	300236	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298484	usd
CY2022Q3	us-gaap	Revenues Revenues	1150	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1150	usd
	us-gaap	Revenues Revenues	320895	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	319143	usd
	us-gaap	Revenues Revenues	2457	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2457	usd
CY2023Q3	BIAF	Cy Path Lung Royalty Income CyPathLungRoyaltyIncome	16107	usd
CY2022Q4	BIAF	Cy Path Lung Royalty Income CyPathLungRoyaltyIncome	4803	usd
CY2023Q3	BIAF	Laboratory Services LaboratoryServices	12390	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables	4730	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBJWWuIQJNLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zgIC7JlDLsId">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $<span id="xdx_903_ecustom--ReclassifiedPatentExpensesAndAnnuityCosts_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_zp1S17uI5KFd" title="Reclassified patent expenses and annuity costs">142,000</span> and $<span id="xdx_905_ecustom--ReclassifiedPatentExpensesAndAnnuityCosts_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_z5idPzRabkF3" title="Reclassified patent expenses and annuity costs">41,000</span> from research and development to selling, general and administrative for the nine months and three months ended September 30, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	BIAF	Property Plant And Equipment Useful Life Description PropertyPlantAndEquipmentUsefulLifeDescription	Lesser of lease term or useful life
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1998553	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1943	usd
CY2023Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1996610	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1943	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1943	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	5686	usd
CY2023Q3	BIAF	Purchased Receivables From Acquisition Net Of Collections PurchasedReceivablesFromAcquisitionNetOfCollections	791852	usd
CY2023Q3	BIAF	Net Patient Fees Receivable NetPatientFeesReceivable	249088	usd
CY2023Q3	BIAF	Histology Fees HistologyFees	31854	usd
CY2023Q3	BIAF	Medical Director Fees MedicalDirectorFees	2393	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	1108414	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	10489	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	240540	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	340078	usd
CY2023Q3	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	30847	usd
CY2022Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	72048	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	111264	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	119773	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	382651	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	848112	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	483617	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	335960	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	269180	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	512152	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
	us-gaap	Depreciation Depreciation	66800	usd
	us-gaap	Depreciation Depreciation	2900	usd
CY2023Q3	us-gaap	Depreciation Depreciation	23500	usd
CY2022Q3	us-gaap	Depreciation Depreciation	800	usd
CY2023Q3	BIAF	Compensation Compensation	554511	usd
CY2022Q4	BIAF	Compensation Compensation	340680	usd
CY2023Q3	BIAF	Legal And Professional LegalAndProfessional	18487	usd
CY2022Q4	BIAF	Legal And Professional LegalAndProfessional	144440	usd
CY2023Q3	BIAF	Clinical Clinical	27776	usd
CY2022Q4	BIAF	Clinical Clinical	50922	usd
CY2023Q3	BIAF	Billing Fees BillingFees	19525	usd
CY2023Q3	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	23487	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	5852	usd
CY2023Q3	BIAF	Accrued Expenses AccruedExpenses	643786	usd
CY2022Q4	BIAF	Accrued Expenses AccruedExpenses	541894	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	38250	usd
CY2023Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y9M29D
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	32081	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	8634	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	9972	usd
	us-gaap	Lease Cost LeaseCost	50687	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	392347	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	90863	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	307397	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1294168	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	32081	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1262087	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	358282	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	929570	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	1287852	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M29D
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0807	pure
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0801	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	28431	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	112126	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	121726	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	448505	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	121726	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	448505	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	121726	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	270395	usd
CY2023Q3	BIAF	Lessee Operating Lease Liability Payments Due Year Four And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter	71007	usd
CY2023Q3	BIAF	Finance Lease Liability Payments Due Year Four And Thereafter FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter	202970	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	464616	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1482501	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	66356	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	194649	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	398260	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	1287852	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	35000	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	15000	usd
	us-gaap	Payments For Rent PaymentsForRent	88000	usd
	us-gaap	Payments For Rent PaymentsForRent	41000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285715	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9350297	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2000000	shares
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	186445	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	79013	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	514313	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	211745	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	64848	shares
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74900	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.84
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	227760	shares
CY2022Q3	us-gaap	Share Price SharePrice	4.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.639	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0220	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares

Files In Submission

Name	View Source	Status
0001493152-23-040986-index-headers.html	Edgar Link	pending
0001493152-23-040986-index.html	Edgar Link	pending
0001493152-23-040986.txt	Edgar Link	pending
0001493152-23-040986-xbrl.zip	Edgar Link	pending
biaf-20230930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
biaf-20230930_cal.xml	Edgar Link	unprocessable
biaf-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
biaf-20230930_lab.xml	Edgar Link	unprocessable
biaf-20230930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2023 Q4 Form 10-Q Financial Statement

#000149315223040986 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2023 Q4 Form 10-Q Financial Statement

#000149315223040986 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf